Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Valdés Delgado TeresaOlmedo Martín RáulIborra MarisaHerrera de Guisé ClaudiaFuentes-Valenzuela EstebanMelcarne LuigiMartín-Rodríguez Mª MarKolle Casso LilyanDe Castro Parga LuisaPonferrada Díaz ÁngelVicente Lidón RaquelManceñido Marcos NoemíVelayos Jiménez BenitoLázaro Sáez MartaLópez Cauce BeatrizMesonero Gismero FranciscoGilabert Álvarez PauArgüelles-Arias FedericoPublished in: Therapeutic advances in gastroenterology (2023)
Evidence on the use of ustekinumab in biological naïve real-world patients is scarce. Here, we present real-world data evaluating the effectiveness and safety of ustekinumab in 84 bio-naïve patients from 17 Spanish hospitals. We report high rates of both clinical and biological remission. Moreover, after 1 year, 90.4% of patients remained being treated with ustekinumab. The safety profile of ustekinumab in these patient population was favourable. In conclusion, our results show that in patients with CD, ustekinumab could be considered as first-line therapy.